Drug Profile
Research programme: Polo-like kinase 1 inhibitors - Cyclacel Pharmaceuticals
Alternative Names: CYC 800 series; CYC800; Plk1 inhibitors - Cyclacel Pharmaceuticals; Polo-like kinase 1 inhibitors - Cyclacel Pharmaceuticals; Research programme: cell cycle modulators - Cyclacel PharmaceuticalsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 04 Apr 2018 Preclinical trials in Solid tumours in USA (PO), prior to April 2018 (Cyclacel pipeline, April 2018)
- 28 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Scotland (PO)